Nkem Ogbechie is Head of Operations Strategic Planning, Risk, and Analytics and is responsible for planning Amgen's internal network capacity and investments to enable the proper technology, platforms, and modalities for Amgen's commercial portfolio and pipeline of emerging products.
Most recently, Nkem served as General Manager for Amgen’s $3 billion bone health franchise (Prolia® and EVENITY®) and brings over 15 years of leadership, strategy, and execution experience in biopharma spanning therapeutic areas, drug development stages, and regions.
Before his General Manager role, Nkem served as Head of Corporate Strategy and led enterprise-wide strategic planning efforts, supported critically integrated actions across our portfolio, target disease areas, and key geographies. Nkem also supported the CEO and CEO staff in the implementation of Amgen’s executive governance system, enabled resource allocation that connected strategy, transformation, and financial performance, and directed CEO regional operating reviews. Nkem joined Amgen in 2011 and led numerous licensing, mergers & acquisitions, and R&D agreement opportunities as a Transaction Lead in Business Development.
Nkem joined Amgen following eight years in investment banking, starting with Goldman Sachs & Company in New York City as part of the healthcare finance group and then in mergers & acquisitions in Los Angeles.
Nkem has a bachelor’s degree in Human Biology from Stanford University, an M.B.A. in Finance and Healthcare Management from Rice University, and a graduate certificate in Biotechnology Management from Harvard University.